IRON
Disc Medicine, Inc.
NASDAQ · Healthcare · Biotechnology · US
$79.23
−0.18%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−9.9x
Market Cap
$3.04B
MomentumView details →
1D Return
−0.18%
YTD Return
+0.24%
RSI (14)
51.9
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−9.9x
Market Cap
$3.04B
RSI (14)
51.9
MomentumView details →
1D Return
−0.18%
YTD Return
+0.24%
SummaryUpdated Jun 1, 2026
Disc Medicine, Inc. (NASDAQ:IRON) is a clinical-stage biotechnology company founded and based in Watertown, Massachusetts. The company went public in August 2020 and focuses on developing novel treatments for patients suffering from serious blood disorders, specifically hematologic diseases. Disc Medicine builds its therapeutic pipeline by targeting fundamental biological pathways related to red blood cell biology, with particular emphasis on heme biosynthesis and iron homeostasis - the processes by which the body produces red blood cells and manages iron levels.
Similar companies
Latest newsMore news →
Disc Medicine, Inc. amended its secured credit facility with Hercules Capital, Inc. on June 25, 2026, extending drawdown periods, splitting the $50 million Tranche 1-C Advance into two $25 million tranches, and drawing down $30 million of the Tranche 1-B Advance.67d agoDisc Medicine completed a Type A meeting with the FDA to discuss the Complete Response Letter for bitopertin in erythropoietic protoporphyria.87d ago